SCA
IMGN

Stonebridge Capital Advisors’s Immunogen Inc IMGN Stock Holding History

Stonebridge Capital Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44
Closed – – 1070
2021
Q3 		$0 Hold
44
– – ﹤0.01% 1138
2021
Q2 		$0 Buy
+44
New +$307 ﹤0.01% 1054

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stonebridge Capital Advisors's IMGN Position: Q4 2021 in Review

Stonebridge Capital Advisors sold out of Immunogen Inc (IMGN) in Q4 2021, closing a stake of 44 shares.

Stonebridge Capital Advisors first reported a position in IMGN in Q2 2021 and held it in 2 quarters. The position peaked at $0 in Q3 2021. 236 funds tracked by Wall St. Rank hold IMGN as of Q4 2021.

  • Stonebridge Capital Advisors reported no remaining Immunogen Inc position as of Q4 2021 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 44 Immunogen Inc shares in Q4 2021.
  • Stonebridge Capital Advisors first reported a position in Immunogen Inc in Q2 2021 and held it in 2 quarters.
  • Stonebridge Capital Advisors's Immunogen Inc position peaked at $0 in Q3 2021.
  • 236 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2021.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.